Dianeal PD-1 with 3.5% Dextrose (lvp solution) Disease Interactions
There are 2 disease interactions with Dianeal PD-1 with 3.5% Dextrose (lvp solution):
Sodium salts (Includes Dianeal PD-1 with 3.5% Dextrose) ↔ sodium/water imbalance
Severe Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Fluid Retention, Hypernatremia, Hypokalemia
Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.
- "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
- "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.
LVP solution (Includes Dianeal PD-1 with 3.5% Dextrose) ↔ hyperglycemia
Moderate Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus
LVP solution for peritoneal dialysis contains dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with these solutions. Blood glucose should me monitored.
More about Dianeal PD-1 with 3.5% Dextrose (lvp solution)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.